MOTS-C is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
First mitochondrial-derived peptide to enter human trials — a 4-week trial of 20 subjects showed glucose reduction and liver enzyme improvement. Extensive animal research documents metabolic, anti-aging, and exercise benefits. Listed by FDA as not approved for compounding. MOTS-C is not fda-approved. listed by fda as unlawful for compounding. available as research chemical only.
What Does the Research Say About MOTS-C?
First mitochondrial-derived peptide to enter human trials — a 4-week trial of 20 subjects showed glucose reduction and liver enzyme improvement. Extensive animal research documents metabolic, anti-aging, and exercise benefits. Listed by FDA as not approved for compounding.
MOTS-C (Mitochondrial ORF of the 12S rRNA Type-C) is a Mitochondrial-derived peptide, metabolic regulator. Research interest has focused on its potential effects on improved insulin sensitivity, glucose metabolism, fat loss, lean muscle preservation, exercise capacity enhancement, anti-aging, metabolic flexibility.
What Is the Evidence for MOTS-C's Mechanism?
Translocates to the nucleus where it regulates gene expression through the Folate-AICAR-AMPK pathway. Activates antioxidant response elements (ARE) and interacts with NRF2 transcription factor to enhance cellular stress resistance. Improves insulin sensitivity and glucose metabolism through AMPK pathway activation, essentially mimicking exercise at the molecular level.
These pathways have been identified through in vitro studies, animal models, and where available, human trials.
Are There Human Clinical Trials for MOTS-C?
First mitochondrial-derived peptide to enter human trials — a 4-week trial of 20 subjects showed glucose reduction and liver enzyme improvement. Extensive animal research documents metabolic, anti-aging, and exercise benefits. Listed by FDA as not approved for compounding.
The gap between preclinical promise and clinical validation remains the biggest challenge in peptide research. However, MOTS-C has shown preliminary results.
What Does the Safety Research Show?
Generally well-tolerated. Mild injection site reactions and transient digestive disturbances at higher doses. CB4211 analog showed good tolerability in a 4-week human trial.
MOTS-C is not fda-approved. listed by fda as unlawful for compounding. available as research chemical only.
What Makes MOTS-C Unique in Research?
The first mitochondrial genome-encoded peptide to enter human testing — essentially exercise in a peptide, activating the same AMPK pathways triggered by physical training.
This differentiator is important because it means MOTS-C fills a role that other compounds in its class may not fully replicate.
Bottom Line on MOTS-C Research
The evidence base for MOTS-C is growing. Key research areas include improved insulin sensitivity, glucose metabolism, fat loss, lean muscle preservation, exercise capacity enhancement, anti-aging, metabolic flexibility.
Stay current with PubMed searches for MOTS-C for the latest publications.
Complete Guide
MOTS-c: The Metabolic Mitochondrial Peptide
Related Reading
- MOTS-C Dosage Guide
- MOTS-C Benefits
- MOTS-C Side Effects
- MOTS-C Stacking Guide
- MOTS-C Cycle Guide
- 5-Amino-1MQ Complete Guide
Calculate Your MOTS-C Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for MOTS-C.
Open Calculator →Research-Grade Sourcing
If you're going to research MOTS-C, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is MOTS-C?
MOTS-C (Mitochondrial ORF of the 12S rRNA Type-C) is a Mitochondrial-derived peptide, metabolic regulator. Encoded by the 12S rRNA region of the mitochondrial genome; naturally produced in response to stress, exercise, and aging. It is researched for improved insulin sensitivity, glucose metabolism, fat loss, lean muscle preservation, exercise capacity enhancement, anti-aging, metabolic flexibility.
What is the recommended MOTS-C dosage?
Common dosages: 5-10 mg per week administered 2-3 times weekly via subcutaneous injection. Cycle length: 8-12 weeks with 8-12 week breaks. Half-life: not established in humans. Use our peptide calculator for exact reconstitution math.
What are the side effects of MOTS-C?
Generally well-tolerated. Mild injection site reactions and transient digestive disturbances at higher doses. CB4211 analog showed good tolerability in a 4-week human trial.
Is MOTS-C safe?
MOTS-C has shown a favorable safety profile in research. Not FDA-approved. Listed by FDA as unlawful for compounding. Available as research chemical only. All research should follow appropriate safety protocols.